Stocks in play: TearLab Corporation
Provided an update on the regulatory strategy for its TearLab Discovery™ System, the Company’s next-generation in-vitro diagnostics testing platform. Based on a reassessment of its regulatory and reimbursement considerations, the Company has elected to pursue initial U.S. Food and Drug Administration (FDA) clearance of a test card measuring a single inflammatory biomarker, MMP-9, in combination with our FDA cleared osmolarity test. TearLab Corporation